Get E&O weekly. | Subscribe
Digital health research from Brian Dolan.
Welcome to E&O.
Last week I wrote about a Senate bill that seeks reimbursement for prescription digital therapeutics. Next week I'm hoping to get wonky about how a piece of software gets coded like a drug. Here's what's happening this week:
- Unusual way to kick off Year Two of E&O: After I suggested that Omada should (and probably would) acquire digital MSK provider Physera last weekend in a rare open-access post on E&O, a few days later Omada did just that. So... welcome to all the new readers, and please ratchet your expectations way, way down.
- Big Health wrote a white paper on the cost-effectiveness of its Sleepio product earlier this month:
"The study assessed baseline healthcare costs for 1,102 employees (551 Sleepio users and 551 controls) during an initial 12-month timeframe, before Sleepio was